89bio to Participate in the BofA Securities 2024 Health Care Conference
89bio, Inc. (Nasdaq: ETNB) will participate in the BofA Securities 2024 Health Care Conference to present their innovative therapies for liver and cardiometabolic diseases.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
89bio, Inc. (Nasdaq: ETNB) will participate in the BofA Securities 2024 Health Care Conference to present their innovative therapies for liver and cardiometabolic diseases. The presentation is scheduled for May 15, 2024, at 2:20 PM PDT.
Details
News Market Reaction – ETNB
The recorded move for ETNB in the trading session of this news was +0.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will present at the BofA Securites 2024 Health Care Conference on Wednesday, May 15, 2024 at 2:20 PM PDT and participate in one-on-one investor meetings.
The webcast of the presentation will be accessible here and in the investor section of 89bio’s website.
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.